These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 30589081)

  • 21. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo.
    Yen HL; Ilyushina NA; Salomon R; Hoffmann E; Webster RG; Govorkova EA
    J Virol; 2007 Nov; 81(22):12418-26. PubMed ID: 17855542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands.
    Wei DQ; Du QS; Sun H; Chou KC
    Biochem Biophys Res Commun; 2006 Jun; 344(3):1048-55. PubMed ID: 16647045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microsecond Molecular Dynamics Simulations of Influenza Neuraminidase Suggest a Mechanism for the Increased Virulence of Stalk-Deletion Mutants.
    Durrant JD; Bush RM; Amaro RE
    J Phys Chem B; 2016 Aug; 120(33):8590-9. PubMed ID: 27141956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Binding pattern of the long acting neuraminidase inhibitor laninamivir towards influenza A subtypes H5N1 and pandemic H1N1.
    Meeprasert A; Khuntawee W; Kamlungsua K; Nunthaboot N; Rungrotmongkol T; Hannongbua S
    J Mol Graph Model; 2012 Sep; 38():148-54. PubMed ID: 23079644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Computational design of novel, high-affinity neuraminidase inhibitors for H5N1 avian influenza virus.
    Park JW; Jo WH
    Eur J Med Chem; 2010 Feb; 45(2):536-41. PubMed ID: 19914748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of secondary sialic acid binding sites in influenza N1 neuraminidase.
    Sung JC; Van Wynsberghe AW; Amaro RE; Li WW; McCammon JA
    J Am Chem Soc; 2010 Mar; 132(9):2883-5. PubMed ID: 20155919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outside-binding site mutations modify the active site's shapes in neuraminidase from influenza A H1N1.
    Tolentino-Lopez L; Segura-Cabrera A; Reyes-Loyola P; Zimic M; Quiliano M; Briz V; Muñoz-Fernández A; Rodríguez-Pérez M; Ilizaliturri-Flores I; Correa-Basurto J
    Biopolymers; 2013 Jan; 99(1):10-21. PubMed ID: 23097226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular dynamics simulation studies on influenza A virus H5N1 complexed with sialic acid and fluorinated sialic acid.
    Jeyaram RA; Priyadarzini TRK; Anu Radha C; Siva Shanmugam NR; Ramakrishnan C; Gromiha MM; Veluraja K
    J Biomol Struct Dyn; 2019 Nov; 37(18):4813-4824. PubMed ID: 30686127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA).
    Mitrasinovic PM
    Biophys Chem; 2009 Mar; 140(1-3):35-8. PubMed ID: 19117662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MD simulation of the interaction between sialoglycans and the second sialic acid binding site of influenza A virus N1 neuraminidase.
    Elli S; Gambacorta N; Rudd TR; Matrosovich M; Guerrini M
    Biochem J; 2021 Jan; 478(2):423-441. PubMed ID: 33410905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insight into the oseltamivir resistance R292K mutation in H5N1 influenza virus: a molecular docking and molecular dynamics approach.
    Karthick V; Ramanathan K
    Cell Biochem Biophys; 2014 Mar; 68(2):291-9. PubMed ID: 23794010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.
    Wu Y; Gao F; Qi J; Bi Y; Fu L; Mohan S; Chen Y; Li X; Pinto BM; Vavricka CJ; Tien P; Gao GF
    J Virol; 2016 Dec; 90(23):10693-10700. PubMed ID: 27654293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In silico prediction of drug resistance due to S247R mutation of Influenza H1N1 neuraminidase protein.
    Mandal RS; Panda S; Das S
    J Biomol Struct Dyn; 2018 Mar; 36(4):966-980. PubMed ID: 28279127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
    Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
    J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of Indonesian clade 2.1 highly pathogenic influenza A(H5N1) viruses with N294S and S246N neuraminidase substitutions which further reduce oseltamivir susceptibility.
    McKimm-Breschkin JL; Barrett S; Wong FYK; Pudjiatmoko ; Azhar M; Selleck P; Davies KR; Hartaningsih N; McGrane J
    Antiviral Res; 2018 May; 153():95-100. PubMed ID: 29574145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An Amino Acid in the Stalk Domain of N1 Neuraminidase Is Critical for Enzymatic Activity.
    Zanin M; Duan S; Wong SS; Kumar G; Baviskar P; Collin E; Russell C; Barman S; Hause B; Webby R
    J Virol; 2017 Jan; 91(2):. PubMed ID: 27847354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding of known drug-target interactions in the catalytic pocket of neuraminidase subtype N1.
    Malaisree M; Rungrotmongkol T; Decha P; Intharathep P; Aruksakunwong O; Hannongbua S
    Proteins; 2008 Jun; 71(4):1908-18. PubMed ID: 18175324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of Residues That Affect Oligomerization and/or Enzymatic Activity of Influenza Virus H5N1 Neuraminidase Proteins.
    Dai M; Guo H; Dortmans JC; Dekkers J; Nordholm J; Daniels R; van Kuppeveld FJ; de Vries E; de Haan CA
    J Virol; 2016 Oct; 90(20):9457-70. PubMed ID: 27512075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus.
    Du QS; Wang SQ; Chou KC
    Biochem Biophys Res Commun; 2007 Oct; 362(2):525-31. PubMed ID: 17707775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation analyses on binding affinity of sialic acid analogues and anti-influenza drugs with human neuraminidase using ab initio MO calculations on their complex structures--LERE-QSAR analysis (IV).
    Hitaoka S; Matoba H; Harada M; Yoshida T; Tsuji D; Hirokawa T; Itoh K; Chuman H
    J Chem Inf Model; 2011 Oct; 51(10):2706-16. PubMed ID: 21870866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.